Clinical Trial

Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma

Name: Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma — clinical trial record (NCT06903273)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TisGCS for BTC

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To investigate the efficacy and tolerability of neoadjuvant tislelizumab, gemcitabine, cisplatin and S-1 (TisGCS) in patients with resectable high-risk iCCA.

Trial Details

NCT Number	NCT06903273
Lead Sponsor	National Cheng-Kung University Hospital Collaborators: Kaohsiung Veterans General Hospital., Chi Mei Medical Hospital
Conditions	Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Enrollment	35 participants
Start Date	2025-07-01
Primary Completion	2028-07-01 (estimated)
Study Completion	2029-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-30